Opsis Therapeutics
Optic Vesicles

Manufacturing Retinal Cells

Prior to advancing any retinal cell therapeutic to the clinic it is first necessary to establish robust manufacturing methods for production of production of iPSC-derived human retinal cells. Quality control and functional requirements for clinical use set a high standard. Our proprietary iPSC and optic vesicle production and differentiation (i.e., maturation) platforms offer considerable advantages for scale-up of high quality cells.

Optic Vesicles

Optic Vesicles

The technique of generating 3-dimensional optic vesicle-like structures from human pluripotent cells was first reported by Meyer et al. in the Gamm laboratory at UW-Madison concurrently with work published using mouse embryonic stem cells by the Sasai laboratory in Japan. These methods have since been independently validated and expanded upon by multiple research teams worldwide. Dr. Gamm's optic vesicle technology, to which our company has obtained exclusive license, provides a method by which to produce retinal cell lineages that display appropriate characteristics.

Retinal Differentiation

Retinal Differentiation

When stained for biologic hallmarks of retinal cells and viewed in cross-section, optic vesicles derived from human iPSCs display distinct time- and location-dependent patterns of retinal cell differentiation. The maturing optic vesicle provides structural and cell-cell cues that enable emergent development of multiple retinal cell types, including photoreceptors and retinal ganglion cells.

Photoreceptor Maturation

Photoreceptor Maturation

As retinal cells mature within the optic vesicle, photoreceptors form specialized structures call outer segments, which contain opsins. Opsins are the molecules in photoreceptors responsible for capturing light, the critical first step in visual perception.